Amalgamated Financial’s 10x Genomics TXG Stock Holding History

Amalgamated Financial’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.49M	Buy	+19,551	New	+$1.71M	0.01%	1018

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Financial's TXG Position: Q1 2022 in Review

Amalgamated Financial opened a new position in 10x Genomics (TXG) in Q1 2022: 19,551 shares worth $1.49M. The stake represents 0.01% of the portfolio and ranks #1018 among its holdings.

314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

Amalgamated Financial held 19,551 shares of 10x Genomics worth $1.49M as of Q1 2022.
10x Genomics was a new Amalgamated Financial position in Q1 2022.
10x Genomics made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1018 holding.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.